Multiple-Dose Safety, Pharmacokinetics, and Pharmacodynamics of the μ-Opioid Receptor Inverse Agonist GSK1521498

• Published in: Journal of clinical pharmacology Vol. 52; no. 10; pp. 1456 - 1467
• Main Authors: Nathan, Pradeep J., Bush, Mark A., Tao, Wenli X., Koch, Annelize, Davies, Kirsty M., Maltby, Kay, O'Neill, Barry V., Napolitano, Antonella, Skeggs, Andrew L., Brooke, Allison C., Richards, Duncan B., Williams, Pauline M., Bullmore, Edward T.
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01-10-2012; SAGE Publications; Wiley Subscription Services, Inc
• Subjects: addiction; Adult; Affect - drug effects; alcohol; cognition; Cognition - drug effects; Double-Blind Method; Drug Administration Schedule; Female; Hot Temperature; Humans; Indans - administration & dosage; Indans - adverse effects; Indans - pharmacokinetics; Male; Middle Aged; obesity; Pain Threshold - drug effects; pharmacodynamics; pharmacokinetics; Pressure; psychiatric adverse effects; Receptors, Opioid, mu - agonists; safety; Triazoles - administration & dosage; Triazoles - adverse effects; Triazoles - pharmacokinetics; Young Adult; μ-Opioid receptor; alcohol; psychiatric adverse effects; cognition; pharmacodynamics; safety; addiction; µ-Opioid receptor; pharmacokinetics; obesity
• ISSN: 0091-2700; 1552-4604
• DOI: 10.1177/0091270011421785

The endogenous opioid system and µ-opioid receptors in particular have been demonstrated to play a fundamental role in hedonic and motivational behaviors reinforced by rewards. In healthy participants, the authors examined the multiple-dose safety, pharmacokinetic, and secondary pharmacodynamic profile of GSK1521498, a µ-opioid receptor inverse agonist that is being developed for treatment of disorders of compulsive consumption. Clinically relevant doses of GSK1521498 (2, 5, and 10 mg) following once-daily administration for 10 days, were well tolerated with no clinically relevant changes in vital signs, chemistry, or hematologic parameters and with a favorable neuropsychiatric profile. Following oral administration, median first time to reach maximum observed plasma concentration for GSK1521498 occurred 2 to 5 hours after dosing, with individual values ranging from 1 to 8 hours. Systemic exposure to GSK1521498 (area under the curve [0–∞] and maximum observed plasma concentration) increased in a slightly greater-than-dose-proportional manner, and steady-state plasma levels were reached within approximately 7 days. The secondary pharmacodynamic effects of GSK1521498 on cognition and pain threshold and tolerance were dose related, with mild to moderate impairments in measures of attention and reductions of pressure pain threshold and tolerance at the highest dose. These findings provide encouraging safety, tolerability, and pharmacokinetic data in support of the continued clinical development of GSK1521498.